Latest advances in breast cancer treatment reported in 2018 annual conference of American Society of Clinical Oncology

doi:10.3877/cma.j.issn.1674-0807.2018.06.002

Abstract

Abstract:

The annual conference of American Society of Clinical Oncology (ASCO) in 2018 showed us the latest advances in chemotherapy, endocrine therapy and immunotherapy for breast cancer. In the field of chemotherapy, there is still an attempt to select people for exemption from chemotherapy or to try to relieve the drug burden. In the development of new compound and in the combination of chemotherapy and targeted therapy, the researchers are looking for more precise and targeted regimens. With regards to endocrine therapy, traditional endocrine drug combined with targeted therapy is still a hot spot. Immunotherapy has been proved effective in metastatic breast cancer, and now researchers are trying to investigate the clinical value of immunotherapy in early breast cancer.

Key words: Breast neoplasms, Chemotherapy, Endocrine therapy, Targeted therapy, Immunotherapy

Zhimin Shao, Yin Liu. Latest advances in breast cancer treatment reported in 2018 annual conference of American Society of Clinical Oncology[J]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(06): 324-328.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2018.06.002

https://zhrxbzz.cma-cmc.com.cn/EN/Y2018/V12/I06/324

References 28

[1]	Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med，2018，379(2):111-121.
[2]	Janni W, Nitz U, Rack BK, et al. Pooled analysis of two randomized phase Ⅲ trials (Plan B/Success C) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n＝5923) [J]. J Clin Oncol，2018，36(15 suppl):522.
[3]	Foukakis T, von Minckwitz G, Bengtsson NO，et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical crial[J]. JAMA，2016，316(18):1888-1896.
[4]	Matikas A, Foukakis T, Moebus V, et al. Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study [J]. J Clin Oncol，2018，36(15 suppl):538.
[5]	Gluz D, Nitz U, Liedtke C, et al. Impact of 12 weeks nab-paclitaxel ＋ carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase Ⅱ trial [J]. J Clin Oncol，2018，36(15 suppl):573.
[6]	Xu BH, Zhang P, Sun T，et al. Phase Ⅲ multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer [J]. J Clin Oncol，2018，36(15 suppl):1003.
[7]	Zhang P, Tong Z, Tian F, et al. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients[J]. J Hematol Oncol，2016，9(1):68.
[8]	Zhang P, Sun T, Zhang Q, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial[J]. Lancet Oncol，2017，18(3):371-383.
[9]	Abramson VG, Lehmann BD, Ballinger TJ, et al. Subtyping of triple-negative breast cancer: implications for therapy[J]. Cancer，2015，121(1):8-16.
[10]	Banerji U, Dean EJ, Pérez-Fidalgo JA, et al. A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers [J]. Clin Cancer Res，2018，24(9):2050-2059.
[11]	Schmid P, Abraham J, Chan S，et al. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase Ⅱ trial [J]. J Clin Oncol，2018，36(15 suppl):1007.
[12]	Dent R, Im SA, Espie M，et al. Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) ＋ paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC) [J]. J Clin Oncol，2018，36(15 suppl):1008.
[13]	Telli ML, Metzger O, Timms K，et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin ＋/－ veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC[J]. J Clin Oncol，2018，36(15 suppl):519.
[14]	Francis PA, Pagani O, Fleming GF，et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J]. N Engl J Med，2018，379(2):122-137.
[15]	Slamon DJ, Neven P, Chia SKL，et al. Ribociclib (RIB) ＋ fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR＋), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3 [J]. J Clin Oncol，2018，36(15 suppl):1000.
[16]	Neven P, Rugo HS, Tolaney SM，et al. Abemaciclib for pre/perimenopausal women with HR＋，HER2- advanced breast cancer[J]. J Clin Oncol，2018，36(15 suppl):1002.
[17]	Kwapisz D．Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib[J]. Breast Cancer Res Treat，2017，166(1):41-54.
[18]	Jerusalem GHM, Kovalenko E, Yardley DA, et al. Everolimus (EVE) ＋ exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER＋), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study [J]. J Clin Oncol，2018，36(15 suppl):1005.
[19]	Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled triall[J]. Lancet，2013，382(9897):1021-1028.
[20]	Ganz PA, Romond EH, Cecchini RS, et al. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2[J]. J Clin Oncol，2017，35(35):3942-3948.
[21]	Perez EA, Romond EH, Suman VJ，et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 [J]. J Clin Oncol，2014，32(33):3744-3752.
[22]	Pivot X, Romieu G, Debled M，et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial[J]. Lancet Oncol，2013，14(8):741-748.
[23]	Conte P, Frassoldati A, Bisagni G，et al. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase Ⅲ randomized Short-HER study [J]. Ann Oncol，2018. doi: 10.1093/annonc/mdy414.
[24]	Cameron D, Piccart-Gebhart MJ, Gelber RD，et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet，2017，389(10 075):1195-1205.
[25]	Earl HM, Hiller L, Vallier AL，et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (＋) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results [J]. J Clin Oncol，2018，36(15 suppl): 506-506.
[26]	Baselga J, Cortés J, Kim SB，et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med，2012，366(2):109-119.
[27]	Urruticoechea A, Rizwanullah M, Im SA，et al. Final overall survival (OS) analysis of PHEREXA: A randomized phase Ⅲ trial of trastuzumab (H) ＋ capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy [J]. J Clin Oncol，2018，36(15 suppl): 1013.
[28]	Pusztai L, Hofstatter EW, Chung GG, et al. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC) [J]. J Clin Oncol，2018，36(15 suppl): 586-586.

Please choose a citation manager

Content to export